PARP inhibitors

Abbott Amgen AstraZeneca Biogen biotech Bristol-Myers Squibb buyouts cancer China diabetes drug stocks drug trials earnings Elan Eli Lilly FDA Genentech generics Genzyme Gilead GSK H1N1 healthcare reform JNJ layoffs Lilly M&A Merck Novartis partnerships patents Pfizer Pharma CEOs Roche Sanofi-Aventis Schering-Plough swine flu Teva vaccines Wyeth